Quantification shows that only 4.3% (13/300) tumor cells remaining at primary injection site (non-invasive cells) were positive for CD133, whereas 42.3% (127/300) invasive cells spread to distant sites expressed CD133 (Figure 4B). The gene discussed is PROM1; the disease is neoplasm.